Compare XBIT & KRMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XBIT | KRMD |
|---|---|---|
| Founded | 2005 | 1980 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Pharmaceuticals and Biotechnology | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 66.8M | 192.5M |
| IPO Year | 2015 | 2019 |
| Metric | XBIT | KRMD |
|---|---|---|
| Price | $2.20 | $3.03 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $6.25 |
| AVG Volume (30 Days) | 36.5K | ★ 226.7K |
| Earning Date | 11-11-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 53.85 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $41,127,366.00 |
| Revenue This Year | N/A | $16.78 |
| Revenue Next Year | $30.47 | $17.22 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 22.23 |
| 52 Week Low | $2.09 | $2.98 |
| 52 Week High | $3.44 | $6.61 |
| Indicator | XBIT | KRMD |
|---|---|---|
| Relative Strength Index (RSI) | 47.52 | 24.92 |
| Support Level | $2.16 | N/A |
| Resistance Level | $2.48 | $3.41 |
| Average True Range (ATR) | 0.04 | 0.13 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 66.67 | 3.06 |
XBiotech Inc is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies derived from human donors to replicate the human immune response in the treatment of various diseases. It has developed a pipeline of product candidates using True Human antibodies targeting both inflammatory and infectious diseases. The company's developement pipeline comprises: Natrunix, an antibody targeting IL-1a in oncology (pancreatic cancer), a clinical stage therapeutic for Methicillin Resistant Staphylococcus aureus (MRSA), and several pre-clinical stage therapeutics, including: an oral delivery antibody therapeutic for colon infection by C. difficile; an injectable therapy for varicella zoster (adult chicken pox), the causative agent for shingles; and an influenza therapy.
KORU Medical Systems Inc develops, manufactures, and commercializes large volume subcutaneous infusion solutions for the subcutaneous drug delivery market. Its product portfolio focuses on mechanical infusion devices, including the FREEDOM60 and FreedomEdge syringe drivers, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing. The company operates as one segment. Its revenue streams are: Domestic Core, International Core and Pharma services and clinical trials. The majority of the company's revenue is derived from the Domestic Core business, which consists of sales of its syringe drivers, tubing and needles. Geographically, its revenues are predominantly derived from the United States.